Analyst Sets Price Target for Cooper Companies (NASDAQ: COO) Amidst Revenue Growth and Strong Free Cash Flow

• An analyst has set a price target of $61.00 for Cooper Companies, which is below its recent trading price, indicating a cautious outlook.
• Despite modest 1% revenue growth, the medical device company achieved a record quarterly free cash flow of $273 million.
• Cooper Companies increased its share repurchase authorization to $3 billion and reported a significant tax benefit of $307.20 million.

Analyst Jeff Johnson from Robert W. Baird sets a price target of $61.00 for Cooper Companies (NASDAQ: COO). Cooper Companies is a global medical device company with two main businesses: CooperVision for contact lenses and CooperSurgical for women's health. The analyst's target is below the stock's recent trading price of $63.48, suggesting a cautious outlook.

The company's third-quarter revenue reached about $1.07 billion, a 1% increase from the previous year. This includes 1% organic growth, which measures sales growth from its core operations. This slight increase comes as Cooper Companies navigates challenges within its CooperVision contact lens business due to planned inventory reductions in the U.S.

Despite modest revenue growth, Cooper Companies generated a record quarterly free cash flow of $273 million. Free cash flow is the cash a company has after paying for its operations and investments, indicating strong financial health. This performance contributed to a year-to-date total of $528 million, an 86% increase from the prior year.

The company's non-GAAP earnings per share (EPS) rose 4% to $1.15. As highlighted by GlobeNewswire, a significant factor in its results was a $307.20 million tax benefit. Following a strategic review, Cooper Companies also decided to keep its CooperSurgical business and increased its share repurchase authorization from $2 billion to $3 billion.